O'Donovan N - Search Results

1

Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer.

Roche S, Gaule P, Winrow D, Mukherjee N, O'Neill F, Conlon NT, Meiller J, Collins DM, Canonici A, Fawsi MI, Estepa-Fernández A, Madden SF, Crown J, O'Donovan N, Eustace AJ. Roche S, et al. Among authors: o donovan n. PLoS One. 2023 Mar 15;18(3):e0282512. doi: 10.1371/journal.pone.0282512. eCollection 2023. PLoS One. 2023. PMID: 36920947 Free PMC article.

2

Survivin: a new target for anti-cancer therapy.

Ryan BM, O'Donovan N, Duffy MJ. Ryan BM, et al. Cancer Treat Rev. 2009 Nov;35(7):553-62. doi: 10.1016/j.ctrv.2009.05.003. Epub 2009 Jun 25. Cancer Treat Rev. 2009. PMID: 19559538 Review.

3

Survey of nuclear medicine practice in Ireland.

O'Donovan N, Hone C, Turvey FJ. O'Donovan N, et al. Ir J Med Sci. 1988 Oct;157(10):310-5. doi: 10.1007/BF02954340. Ir J Med Sci. 1988. PMID: 3229957 No abstract available.

4

Growth hormone regulates growth hormone receptor gene transcription in primary human thyroid cells.

Mullis PE, O'Donovan N, Eblé A, Marti U, Diem P, Bürgi U, Peter HJ. Mullis PE, et al. Mol Cell Endocrinol. 2000 Aug 30;166(2):111-9. doi: 10.1016/s0303-7207(00)00272-0. Mol Cell Endocrinol. 2000. PMID: 10996429

5

Differential expression of IgG Fc binding protein (FcgammaBP) in human normal thyroid tissue, thyroid adenomas and thyroid carcinomas.

O'Donovan N, Fischer A, Abdo EM, Simon F, Peter HJ, Gerber H, Buergi U, Marti U. O'Donovan N, et al. J Endocrinol. 2002 Sep;174(3):517-24. doi: 10.1677/joe.0.1740517. J Endocrinol. 2002. PMID: 12208673

6

Caspase 3 in breast cancer.

O'Donovan N, Crown J, Stunell H, Hill AD, McDermott E, O'Higgins N, Duffy MJ. O'Donovan N, et al. Clin Cancer Res. 2003 Feb;9(2):738-42. Clin Cancer Res. 2003. PMID: 12576443

7

Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer.

Ryan B, O'Donovan N, Browne B, O'Shea C, Crown J, Hill AD, McDermott E, O'Higgins N, Duffy MJ. Ryan B, et al. Br J Cancer. 2005 Jan 17;92(1):120-4. doi: 10.1038/sj.bjc.6602314. Br J Cancer. 2005. PMID: 15611790 Free PMC article.

8

EGFR and HER-2 antagonists in breast cancer.

O'Donovan N, Crown J. O'Donovan N, et al. Anticancer Res. 2007 May-Jun;27(3A):1285-94. Anticancer Res. 2007. PMID: 17593621 Free article. Review.

9

The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells.

Glynn SA, O'Sullivan D, Eustace AJ, Clynes M, O'Donovan N. Glynn SA, et al. BMC Cancer. 2008 Jan 16;8:9. doi: 10.1186/1471-2407-8-9. BMC Cancer. 2008. PMID: 18199328 Free PMC article.

10

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.

Eustace AJ, Crown J, Clynes M, O'Donovan N. Eustace AJ, et al. J Transl Med. 2008 Sep 29;6:53. doi: 10.1186/1479-5876-6-53. J Transl Med. 2008. PMID: 18823558 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

102 results

Search Page